Medicine & Life Sciences
Primary Myelofibrosis
100%
Systemic Mastocytosis
57%
Polycythemia Vera
43%
Mutation
40%
Essential Thrombocythemia
36%
Survival
27%
Mastocytosis
17%
Karyotype
17%
Eosinophilia
16%
Myelodysplastic Syndromes
16%
Imatinib Mesylate
14%
Mast Cells
14%
N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide
13%
Janus Kinase Inhibitors
13%
Neoplasms
12%
Cytogenetics
12%
Therapeutics
11%
Leukemia
10%
Hypereosinophilic Syndrome
10%
INCB018424
9%
Acute Myeloid Leukemia
9%
Fedratinib
9%
Bone Marrow
9%
Myeloproliferative Disorders
9%
Leukemia, Myelomonocytic, Chronic
9%
Janus Kinase 2
8%
Blast Crisis
8%
Hemoglobins
8%
Calreticulin
8%
Risk Management
7%
Cladribine
7%
Thrombosis
7%
Anemia
7%
venetoclax
6%
Platelet Count
6%
Splenomegaly
6%
Alleles
6%
Scapharca
5%
Chromosome Aberrations
5%
Abnormal Karyotype
5%
pomalidomide
5%
Mast-Cell Leukemia
5%
Leukemia, Neutrophilic, Chronic
5%